A mid valuation concerns, investors are turning to .defensive sectors. The pharmaceutical (pharma) sector has benefited from this shift, attracting investors seeking steady cash flows. On Friday, while most sectoral indices closed in the negative, the pharma index ended with gains. Over the past month, the Nifty Pharma, with a gain of 7 per cent, has outperformed other indices; the Nifty 50's returns were capped at 1.6 per cent.
Over the past three months, the pharma index was the second highest gainer with a 14 per cent return, compared to a 10 per cent return for the Nifty 50.
Among the top-listed pharma companies, average returns have exceeded 20 per cent, except for Cipla. The recent boost for listed pharma majors has come from their robust performance in the April-June quarter. Most major companies either surpassed or met Street estimates for sales, with operating margins and net profits exceeding expectations.
Bu hikaye Business Standard dergisinin August 05, 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye Business Standard dergisinin August 05, 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
IT stocks suffer biggest one-day fall in six weeks
Accenture promotion delay, past Fed rate cuts cited
Cabinet clears 'One Nation, One Poll' and host of proposals in farm to space
Soon after completing 100 days in office, the National Democratic Alliance (NDA) government has taken a series of decisions that would have political and economic implications for the country.
Tata Power to scale up internal RE component supply chain
Plans to manufacture key parts rather than buying them
IT staffers' FY25 salary hikes may be 5.5-8%
Experts say top performers may continue to see increases ranging from 12-18%
RInfra pares debt by 87% to ₹475 cr
Anil Ambani group firm Reliance Infrastructure (RInfra) and its subsidiary Reliance Power (RPower) have cleared a major part of their debt, with RInfra reducing its standalone external borrowing by almost 87.6 per cent to ₹475 crore, down from ₹3,831 crore as on June, according to stock exchange notices.
'No plans to phase out Kwid until rules allow'
Renault India, which saw a 33 per cent decline in sales in 2023, is facing a challenging 2024. The company's Managing Director and Chief Executive Officer VENKATRAM MAMILLAPALLE, discusses the firm's revival plans, launch strategy, and the future of the Kwid in an interaction with Shine Jacob in Chennai. Edited excerpts:
25-year-old company veteran Samir Kumar has cart full as he takes reins at Amazon India
Amazon has announced that Samir Kumar, a 25-year veteran of the company, will assume the role of head of its India consumer business effective October 1, 2024.
ZEEL refutes $940 mn Disney Star claim over ICC TV rights deal
Star India on Monday filed a statement of case seeking $940 million damages from Zee Entertainment Enterprises (ZEEL) over the terminated ICC TV rights deal, the latter said in a stock exchange filing.
Best option is to double down on mkt strategy: P&G India
Procter & Gamble Hygiene and Healthcare (PGHH) and Gillette India (GI), both listed entities of Procter & Gamble India, noted in their investor calls that despite near-term macroeconomic challenges, an above normal monsoon will help revive demand in India.
'Irreparable loss for us': EY India on death of CA
The death of 26-year-old chartered accountant Anna Sebastian Perayil is \"tragic\" and an \"irreparable loss\" for EY India, the company said in a statement on Wednesday.
